• N6-Methyl-dATP for Mechanistic AML Assays

  2026-09-22

  Explore how N6-Methyl-dATP can connect polymerase biochemistry with AML pathway research without overinterpreting cellular findings. This article translates the LMO2–LDB1 study into a rigorous assay-design framework for DNA replication fidelity, methylation modification research, and genomic stability epigenetics.

• rTMS Activates Cx3cl1–Cx3cr1 Signaling in AD

  2026-09-22

  This study identifies a cellular mechanism by which repetitive transcranial magnetic stimulation may improve Alzheimer’s disease phenotypes: activation of GABAergic neurons increases Cx3cl1 signaling and enhances microglial amyloid clearance. Its integrated use of single-cell transcriptomics, plaque analysis, microglial phenotyping, and inflammatory readouts provides a framework for connecting neuromodulation with immune regulation in the brain.

• Recombinant Annexin V and Endothelial Thrombin Formation

  2026-09-21

  The 1994 reference study moved Annexin V research from model phospholipid vesicles to cultured human endothelial cells, quantifying both cell-surface binding and inhibition of coagulation reactions. Its findings show that recombinant Annexin V binds quiescent and stimulated endothelial cells with similar affinity while efficiently suppressing factor Xa and thrombin generation on the cell surface.

• Obeticholic Acid in FXR Liver Fibrosis Models

  2026-09-21

  Obeticholic Acid offers a receptor-proximal way to connect bile acid homeostasis, cholestasis, inflammation, and fibrosis phenotypes in translational liver experiments. This workflow combines FXR gene readouts with histology, biochemical endpoints, and the immune-resolution framework emerging from contemporary liver fibrosis research.

• BOP Reagent Workflows for Prodrug Synthesis

  2026-09-20

  BOP reagent enables controlled carboxyl group activation for peptide coupling, phenyl ester preparation, and linker construction in small-molecule workflows. This guide translates the reagent into practical experimental steps and connects its synthetic utility with carrier-free triterpene prodrug research in oral squamous cell carcinoma.

• Morin Workflows for Podocyte Energy Research

  2026-09-19

  Morin enables a mechanistic workflow linking fructose exposure, AMPD activity, mitochondrial dysfunction, and podocyte injury. Its water-insoluble formulation and fluorescent metal-chelating behavior also make it useful for controlled cell assays and aluminum-ion detection when appropriate controls are included.

• Amyloid Beta-peptide (25-35) Workflow Guide

  2026-09-19

  Build a controlled Aβ25-35 neurotoxicity workflow that connects neuronal injury, oxidative stress, mitochondrial dysfunction, and amyloid aggregation readouts. Extend the model into microglial inflammation studies by testing pathway-level responses alongside FLOT1–FOSL2–EphA2 signaling.

• Parathyroid hormone (1-34) in CKD Research

  2026-09-18

  A translational guide to using Parathyroid hormone (1-34) (human) to connect receptor-proximal calcium signaling with bone remodeling and CKD-associated valvular calcification, while highlighting experimental controls, model selection, and opportunities beyond conventional product-page descriptions.

• Morin, AMPD2, and Podocyte Energy Metabolism

  2026-09-17

  A 2025 study identifies AMPD2-linked purine nucleotide cycling as a mechanistic connection between fructose exposure, mitochondrial energy failure, and podocyte injury. Its combination of rat phenotyping, MPC5-cell experiments, molecular docking, and AMPD2 silencing supports Morin as a tool for investigating metabolic mechanisms in glomerular disease.

• Human iPSC Sensory Neurons Model HSV-1 Latency

  2026-09-17

  Oh et al. developed a scalable human iPSC-derived sensory neuron system that supports experimentally defined HSV-1 latency and reactivation. By combining neuronal functional validation with infectious-virus, viral-transcript, and chromatin-based endpoints, the study provides a human-relevant platform for investigating neuron-intrinsic mechanisms that are difficult to resolve in animal models.

• 3-Bromopyruvate Overcomes Cetuximab Resistance

  2026-09-16

  This study shows that combining 3-bromopyruvate with cetuximab can suppress colorectal cancer cells that are intrinsically or adaptively resistant to cetuximab. The proposed mechanism links FOXO3a restoration to AMPKα–Beclin1 signaling, PUMA activation, autophagy-dependent ferroptosis, and apoptosis, providing a mechanistic framework for studying resistance-directed combination therapy.

• Exercise, Muscle EVs, and Microglial Plaque Clearance

  2026-09-16

  This Nature Aging study identifies skeletal muscle-derived extracellular vesicles as a signaling route through which swimming exercise improves Alzheimer’s disease-related cognition. The work connects the vesicle cargo miR-378a-3p with p110α-dependent lipid regulation in disease-associated microglia, providing a mechanistic explanation for enhanced amyloid-beta plaque clearance.

• EZ Cap Cy5 Firefly Luciferase mRNA Workflow

  2026-09-15

  Build a dual-readout workflow that distinguishes mRNA uptake from productive protein expression using Cy5 fluorescence and firefly luciferase. This guide connects practical mRNA delivery and transfection optimization with the extrahepatic delivery questions raised by recent CORE lipid nanoparticle research.

• Topotecan: Pharmacology and Clinical Evidence

  2026-09-15

  The 1999 review by Kollmannsberger and colleagues positioned Topotecan as a clinically viable, water-soluble topoisomerase I inhibitor by connecting its cleavable-complex mechanism with pharmacokinetic and early clinical evidence. Its findings clarify how lactone stability, renal elimination, schedule, and limited cross-resistance shaped the development of Topotecan for cancer research.

• Morin: From Flavonoid to Podocyte Assay Strategy

  2026-09-14

  Morin is a mechanistically informative flavonoid for connecting AMPD activity, mitochondrial energy failure, and podocyte injury. This article translates recent evidence into a practical assay strategy while defining how its fluorescent metal-chelation behavior can complement, but not replace, disease-model readouts.

7904 records 1/527 page Next 12345 下5页 Last page